First Time Loading...

Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 5.2194 USD 0.96%
Updated: May 3, 2024

Aurinia Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurinia Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
ZYME
TH
RPTX
FUSN
EDT

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Income
-$91.7m
CAGR 3-Years
4%
CAGR 5-Years
-10%
CAGR 10-Years
-36%
Zymeworks Inc
NYSE:ZYME
Operating Income
-$138.1m
CAGR 3-Years
10%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Operating Income
-$7.5m
CAGR 3-Years
27%
CAGR 5-Years
-30%
CAGR 10-Years
2%
Repare Therapeutics Inc
NASDAQ:RPTX
Operating Income
-$116.2m
CAGR 3-Years
-30%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Operating Income
-$99.2m
CAGR 3-Years
-38%
CAGR 5-Years
-58%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Operating Income
-CA$11.7m
CAGR 3-Years
-9%
CAGR 5-Years
-38%
CAGR 10-Years
0%

See Also

What is Aurinia Pharmaceuticals Inc's Operating Income?
Operating Income
-91.7m USD

Based on the financial report for Dec 31, 2023, Aurinia Pharmaceuticals Inc's Operating Income amounts to -91.7m USD.

What is Aurinia Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-36%

Over the last year, the Operating Income growth was 18%. The average annual Operating Income growth rates for Aurinia Pharmaceuticals Inc have been 4% over the past three years , -10% over the past five years , and -36% over the past ten years .